Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Alteogen announced that its major subsidiary, Altos Biologics, will absorb and merge with affiliated company Alteogen Healthcare (Merger Date: December 24, 2024) to integrate organizational structures and enhance management efficiency.
📊 [Key Disclosure Details & Financial Highlights]
- Target Subsidiary: Altos Biologics Corp. (CEO: Hee Jeong Ji, Main Business: Biopharmaceutical R&D, Major Subsidiary: Yes)
- Total Assets of Subsidiary: KRW 63.59B (24.83% of parent company’s consolidated total assets of KRW 256.10B)
- Target Merger Partner: Alteogen Healthcare Inc. (Main Business: Pharmaceutical Wholesale, Affiliate)
- Recent Financials (FY2023): Total Assets KRW 3,674M / Total Liabilities KRW 15,836M / Total Equity KRW -12,162M (Capital Deficit) / Revenue KRW 61M / Net Loss KRW -577M
- Method & Purpose of Merger: Absorption merger of Alteogen Healthcare Inc. (dissolved) by Altos Biologics Corp. (surviving) / Enhancing operational efficiency through organizational integration
- Merger Ratio: Altos Biologics Corp. : Alteogen Healthcare Inc. = 1.0000000 : 0.274192
- New Shares to Issue: 1,390,130 Common Shares / 277,970 Preferred Shares
- Key Scheduled Timelines:
- Scheduled Shareholders Meeting Date: 2024-11-22
- Creditor Objection Period: 2024-11-23 ~ 2024-12-23
- Merger Date: 2024-12-24
- Scheduled Merger Registration Date: 2024-12-30
- Board Resolution Date: 2024-11-07
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Completion of Scheduled Merger Steps
This filing details the decision for an intra-group absorption merger to streamline organizational structure and operational efficiency. Verifying whether shareholder approvals (scheduled for November 22, 2024) and creditor objection procedures proceed smoothly toward the target merger date of December 24, 2024, is important to track corporate restructuring progress. Further status updates can be confirmed in future disclosures or upcoming periodic business reports on DART.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
